Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 9 , ISSUE 1 ( January-June, 2020 ) > List of Articles

Original Article

Prevalence of Multidrug-Resistant Tuberculosis at a Regional Drug-Resistant Tuberculosis Center of Maharashtra

Gauri Suhas Kulkarni, Supriya Dhakne Palwe, Nilesh P. Patil, Abhijit J. Telkhade, Jui Kadukar

Keywords : Isoniazid, multidrug-resistant directly observed therapy, rifampicin, tuberculosis

Citation Information : Kulkarni GS, Palwe SD, Patil NP, Telkhade AJ, Kadukar J. Prevalence of Multidrug-Resistant Tuberculosis at a Regional Drug-Resistant Tuberculosis Center of Maharashtra. Indian J Respir Care 2020; 9 (1):30-34.

DOI: 10.4103/ijrc.ijrc_10_19

License: CC BY-NC-SA 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2020; Indian Journal of Respiratory Care.


Introduction: Multidrug-resistant tuberculosis (MDR-TB) has created a significant health problem in most of the countries, and it is an obstacle to effective TB control. Aims and Objectives: The study aims to study the prevalence of MDR-TB among new cases, retreatment cases and to study the rate of MDR-TB detection among suspected cases of Category I (CAT I) failure, CAT II failure and at the start of CAT II. Patients and Methods: The present retrolective study was conducted by reviewing the records of diagnosed MDR-TB patients at a drug-resistant TB center from January 2012 to December 2013. The data of new and retreatment pulmonary TB (PTB) cases diagnosed during that period were collected. The data were analyzed to find out the prevalence of MDR-TB, and the rate of MDR-TB detected among each CAT. Results: The prevalence of MDR-TB in new cases was 0.10% and that of retreatment cases was 4.3%. The rate of MDR-TB detection among suspected cases of CAT I failure was 16.8%, 52.4% in CAT II failure, 11.6% at the start of CAT II, 11.7% among sputum positive during any month follow-up, 6.6% among MDR-TB contacts. Conclusion: Timely suspicion and diagnosis of MDR-TB and treatment are important in new and retreatment cases. All relapse or defaulter patients should be screened for MDR-TB at the start of CAT II treatment. MDR-TB should be suspected in any sputum-positive TB patient during treatment/sputum positive relapse/defaulter PTB.

  1. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhavan. Guidelines on Programmatic Management of Drug Resistant TB in India. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhavan; 2012.
  2. WHO Treatment Guidelines for Drug Resistant Tuberculosis. 2016 Update. Annexes 4.5 & 6. The End TB Strategy. World Health Organization, 2016.
  3. Varaine F, Rich M. Tuberculosis- Practical Guide for Clinicians, Nurses, Laboratory Technicians and Medical Auxillaries. 2014 Edition. Medicines Sans Frontiers & Partners in Health Publication; 2014.
  4. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202.
  5. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: A cross sectional study. BMC Infect Dis 2011;11:28.
  6. Paramasivan CN. An overview on drug resistant TB in India. Indian J Tuberc 1998;45:73-81.
  7. Cohn DL, Bustero F, Raviglion MC. Drug resistant TB review of the worldwide situation and the WHO/IUATLD Global surveillance project. Clin Infect Dis 1997;24:121-30.
  8. Sharma SK, Kaushik G, Jha B, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J Med Res 2011;133:308-11.
  9. Angrup A, Varma-Basil M, Kumar S, Pathak RK, Sharma H, Banavaliker JN. Drug resistance among Mycobacterium tuberculosis isolates from private clinics and a dots center in Delhi, India. Southeast Asian J Trop Med Public Health 2011;42:122-7.
  10. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2009;4:19-23.
  11. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, et al. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003;36:e152-4.
  12. Mistry N, Tolani M, Osrin D. Drug-resistant tuberculosis in Mumbai, India: An Agenda for operations research. Oper Res Health Care 2012;1:45-53.
  13. Rahman M, Kamal S, Mohammed F, Alam M, Ahasan H. Anti-tuberculosis drug resistance pattern among different category of tuberculosis patients. J Med 2009;10:45-7.
  14. Singh DP, Kumar S, Singh GV, Gupta RK, Chauhan DS, Amir Mohammad A. Multidrug resistant (MDR) tuberculosis in MDR suspect patients and assessment of various reasons for developing drug resistance. Indian J Sci Res Technol 2015;3:26-30.
  15. Ghafoor A, Mehraj J, Afridi ND, Rafiq Y, Wendl-Richter HU, Hasan R. Multidrug resistant Mycobacterium tuberculosis amongst category I and II failures and category II relapse patients from Pakistan. Int J Mycobacteriol 2012;1:118-23.
  16. Kandi S, Prasad SV, Sagar Reddy PN, Reddy VC, Laxmi R, Kopuu D, et al. Prevalence of multidrug resistance among retreatment pulmonary tuberculosis cases in a tertiary care hospital, Hyderabad, India. Lung India 2013;30:277-9.
  17. Burugina Nagaraja S, Satyanarayana S, Chadha SS, Kalemane S, Jaju J, Achanta S, et al. How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India? PLoS One 2011;6:e25698.
  18. Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: A study from China. Thorax 2012;67:632-8.
  19. Dholakia YN, Shah DP. Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program. Lung India 2013;30:316-20.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.